FIELD: chemistry.SUBSTANCE: present invention relates to a heterocyclic compound of chemical formula 1, or a pharmaceutically acceptable salt thereof:[Chemical formula 1].In chemical formula 1: n is equal to 1 or 2, L is -CH2CH2-, -CH=C(R')- or -C≡C-, where R' is hydrogen, C1-4 alkyl or halogen, X1 is CR1R2, NR1 or -CO-, X2 is CR3R4 or NR3, where R1-R4 , each independently represent hydrogen, C1-4 alkyl, C1-4 hydroxyalkyl, hydroxy, amino, carboxy, -COO(C1-4 alkyl), -CONH2, -CONH(C1-4 alkyl), -CON(C1-4 alkyl)2, or pyrazolyl, unsubstituted or substituted with C1-4 haloalkyl； or R1 and R3 together with each other link X1 and X2 through a double bond, and A is a benzene, pyridine, pyrimidine or pyrimidinedione ring, where A is unsubstituted or substituted with one to three substitutes, each of which is independently selected from group consisting of a ring type substitute, selected from a group consisting of furanyl, imidazolyl, isoxazolyl, phenyl, pyrazolyl, pyridinonyl, pyridinyl, pyrrolyl, thiazolyl and thiophenyl； C1-4 alkyl； C1-4 alkoxy； C1-4 haloalkyl； C1-4 haloalkoxy； halogen； di(C1-4 alkyl) amino； nitro； -COO(C1-4 alkyl)； dihydropyranyl； morpholino； piperidinyl； and pyrrolidinyl； and where the ring-type substituent is unsubstituted or substituted with one or two substitutes, each of which is independently selected from a group consisting of C1-5 alkyl, C1-4 haloalkyl, C3-6 cycloalkyl, -COO(C1-4 alkyl), halogen, cyano, thiazolyl and (1,3-dioxolan-2-yl) methyl. Also presented is a pharmaceutical composition and methods of producing the compound.EFFECT: disclosed compound has inhibitory action on the enzymatic activity of prolyl-tRNA synthetase (PRS) and can be used for preventing or treating diseases caused by PRS anomaly activity.15 cl, 3 tbl, 230 exНастоящее изобретение относится к гетероциклическому соединению, представленному химической формулой 1, или его фармацевтически приемлемой соли:[Химическая формула 1].В химической формуле 1: n равно 1 или 2, L предста
